Cellectis Reports Second Quarter 2026 Financial Results
Cellectis announced its financial results for the second quarter of 2026. The company received FDA RMAT designation for lasme-cel and anticipates key clinical analyses later this year.
Biotechnology company Cellectis has released its financial results for the second quarter of 2026. As of June 30, 2026, the company reported cash, cash equivalents, and fixed-term deposits totaling $169 million, providing a runway into the fourth quarter of 2027.
In June 2026, the U.S. Food and Drug Administration (FDA) granted Cellectis Regenerative Medicine Advanced Therapy (RMAT) designation for its lasme-cel drug candidate. This designation was awarded based on promising efficacy data in treating relapsed or refractory B-cell acute lymphoblastic leukemia.
The company also presented full Phase 1 clinical data from the BALLI-01 trial at the European Hematology Association (EHA) 2026 congress. A first interim analysis from the pivotal Phase 2 study is expected in the fourth quarter of 2026.
In parallel, clinical data from the Phase 1 study of eti-cel, another of the company's allogeneic CAR-T candidates, were also presented at EHA. The full Phase 1 dataset is anticipated in the fourth quarter of 2026.
"The lasme-cel and eti-cel clinical results are promising for patients with relapsed or refractory B-cell malignancies," stated Cellectis CEO André Choulika. "We remain focused on advancing new options for people whose disease has returned or stopped responding to available therapies."